PMID- 35968588
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20221231
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 43
IP  - 6
DP  - 2022 Jun 14
TI  - [The correlation of CD49d expression pattern with molecular genetics and hotspot 
      gene mutants in patients with chronic lymphocytic leukemia].
PG  - 463-468
LID - 10.3760/cma.j.issn.0253-2727.2022.06.004 [doi]
AB  - Objective: To explore the correlation of CD49d expression patterns with molecular 
      genetics and hotspot gene mutants in patients with chronic lymphocytic leukemia. 
      Methods: The expression of CD49d was detected by flow cytometry and grouped into 
      homogeneous, bimodal, negative and positive expression. Panel fluorescence in 
      situ hybridization (FISH) was used for molecular genetics analysis and 
      next-generation sequencing (NGS) was conducted for gene mutation detection. 
      Results: There were 43 patients (23.89% ) with positive CD49d expression, 137 
      patients (76.11% ) with negative CD49d expression, 96 patients (53.33% ) with 
      homogeneous CD49d expression and 84 patients (46.67% ) with bimodal CD49d 
      expression. Compared with patients in the CD49d negative group, patients in the 
      CD49d positive group had higher Rai stage (P=0.048) and higher proportion of 
      spleen enlargement (P=0.030) . Compared with patients with homogeneous expression 
      of CD49d, patients with bimodal expression of CD49d had a higher proportion of 
      spleen enlargement (P=0.009) . The expression rate of 11q22- in bimodal CD49d(-) 
      group was significantly higher than that in homogeneous CD49d(-) group (24.29% vs 
      10.45% , P=0.043) . The incidence of +12 in homogeneous CD49d group was higher 
      than that in bimodal CD49d group (16.67% vs 5.95% , P=0.035) . The incidence of 
      +12 in homogeneous CD49d(+) group was higher than that in bimodal CD49d(-) group 
      (17.24% vs 4.29% , P=0.045) . The incidence of +12 in homogeneous CD49d(-) group 
      was higher than that in bimodal CD49d(-) group (16.42% vs 4.29% , P=0.024) . 
      BIRC3 mutation rate in CD49d positive group was higher than that in CD49d 
      negative group (11.63% vs 2.92% , P=0.037) . Conclusion: There were significant 
      correlations between CD49d and 11q22-, +12 and BIRC3 gene mutation. Patients with 
      bimodal CD49d were more correlated with poor prognosis indexes.
FAU - Zhu, J
AU  - Zhu J
AD  - Department of Clinical Laboratory, The Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital) , Institute of Basic 
      Medicine and Cancer (IBMC) , Chinese Academy of Sciences, Hangzhou 310022, China.
FAU - Liu, L
AU  - Liu L
AD  - The First Affiliated Hospital of Nanjing Medical University, Department of 
      Hematology, Jiangsu Province Hospital, Nanjing 210029, China.
FAU - Chen, X
AU  - Chen X
AD  - The First Affiliated Hospital of Nanjing Medical University, Department of 
      Hematology, Jiangsu Province Hospital, Nanjing 210029, China.
FAU - Liu, F
AU  - Liu F
AD  - The First Affiliated Hospital of Nanjing Medical University, Department of 
      Hematology, Jiangsu Province Hospital, Nanjing 210029, China.
FAU - Zhao, S S
AU  - Zhao SS
AD  - The First Affiliated Hospital of Nanjing Medical University, Department of 
      Hematology, Jiangsu Province Hospital, Nanjing 210029, China.
FAU - Jin, H M
AU  - Jin HM
AD  - The First Affiliated Hospital of Nanjing Medical University, Department of 
      Hematology, Jiangsu Province Hospital, Nanjing 210029, China.
FAU - Qiu, H R
AU  - Qiu HR
AD  - The First Affiliated Hospital of Nanjing Medical University, Department of 
      Hematology, Jiangsu Province Hospital, Nanjing 210029, China.
FAU - Qiao, C
AU  - Qiao C
AD  - The First Affiliated Hospital of Nanjing Medical University, Department of 
      Hematology, Jiangsu Province Hospital, Nanjing 210029, China.
FAU - Li, J Y
AU  - Li JY
AD  - The First Affiliated Hospital of Nanjing Medical University, Department of 
      Hematology, Jiangsu Province Hospital, Nanjing 210029, China.
FAU - Wu, Y J
AU  - Wu YJ
AD  - The First Affiliated Hospital of Nanjing Medical University, Department of 
      Hematology, Jiangsu Province Hospital, Nanjing 210029, China.
LA  - chi
GR  - 81370656/National Natural Science Foundation of China/
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Biomarkers, Tumor)
RN  - 143198-26-9 (Integrin alpha4)
RN  - EC 2.3.2.27 (BIRC3 protein, human)
RN  - EC 2.3.2.27 (Baculoviral IAP Repeat-Containing 3 Protein)
SB  - IM
MH  - Baculoviral IAP Repeat-Containing 3 Protein/genetics/metabolism
MH  - Biomarkers, Tumor/metabolism
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Integrin alpha4/genetics/metabolism
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/genetics/metabolism
MH  - Molecular Biology
MH  - Prognosis
PMC - PMC9800228
OTO - NOTNLM
OT  - CD49d
OT  - Flow cytometry
OT  - Gene mutation
OT  - Molecular genetics
COIS- 利益冲突 所有作者声明无利益冲突
EDAT- 2022/08/16 06:00
MHDA- 2022/08/17 06:00
PMCR- 2022/06/01
CRDT- 2022/08/15 04:18
PHST- 2022/08/15 04:18 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
PHST- 2022/06/01 00:00 [pmc-release]
AID - cjh-43-06-463 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2022.06.004 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):463-468. doi: 
      10.3760/cma.j.issn.0253-2727.2022.06.004.